The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

Moderna does not plan to ‌invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

The recombinant, protein-based vaccine is one of only a handful of acne vaccines worldwide promising alternative treatment.

Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...

The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.

This article explores how next-generation vaccines are expanding beyond infectious disease to target chronic conditions while ...

Think you're immune to misinformation? Time for a fact booster.

The head of the Department of Health and Human Services has spent decades promoting vaccine skepticism and has now revamped the US childhood immunization schedule to have one-third fewer recommended ...

A Covid vaccine researcher claims she was silenced for years right before warning the public about the dangers to certain ...